Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
McKinsey
Merck
Moodys
Boehringer Ingelheim

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR LEVOCETIRIZINE DIHYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Levocetirizine Dihydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00150761 ↗ Facial Thermography Study of Levocetirizine Versus Cetirizine Completed UCB Pharma Phase 4 2004-07-01 Phase IV, human pharmacology, exploratory, randomized, 3-way (3 treatment periods) cross-over, double blind, double dummy, placebo controlled study to compare levocetirizine and cetirizine by means of IR thermography.
NCT00152412 ↗ Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis Completed UCB Pharma Phase 2 2004-06-01 4 week open study to evaluate the safety of levocetirizine in young children (2 - 6 years) suffering from allergic rhinitis. As secondary objective, this study will assess the efficacy of the treatment by means of the T4SS (Total 4 symptoms scores of allergic rhinitis) and each of the 4 individual rhinitis symptom scores
NCT00152464 ↗ Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM) Completed UCB Pharma Phase 3 2002-03-20 The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Levocetirizine Dihydrochloride

Condition Name

Condition Name for Levocetirizine Dihydrochloride
Intervention Trials
Allergic Rhinitis 12
Rhinitis 7
Rhinitis, Allergic, Seasonal 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Levocetirizine Dihydrochloride
Intervention Trials
Rhinitis 36
Rhinitis, Allergic 32
Urticaria 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Levocetirizine Dihydrochloride

Trials by Country

Trials by Country for Levocetirizine Dihydrochloride
Location Trials
United States 70
Spain 7
Germany 6
India 5
France 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Levocetirizine Dihydrochloride
Location Trials
Oklahoma 4
Georgia 4
California 4
Missouri 4
Tennessee 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Levocetirizine Dihydrochloride

Clinical Trial Phase

Clinical Trial Phase for Levocetirizine Dihydrochloride
Clinical Trial Phase Trials
Phase 4 29
Phase 3 18
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Levocetirizine Dihydrochloride
Clinical Trial Phase Trials
Completed 57
Unknown status 3
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Levocetirizine Dihydrochloride

Sponsor Name

Sponsor Name for Levocetirizine Dihydrochloride
Sponsor Trials
UCB Pharma 30
GlaxoSmithKline 5
Hanmi Pharmaceutical Company Limited 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Levocetirizine Dihydrochloride
Sponsor Trials
Industry 59
Other 25
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKesson
Merck
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.